Supplemental Information (Tables)

6 Months Ended

Jun. 30, 2020

Geographic Areas, Long-Lived Assets [Abstract]

Schedule of Long-Lived Assets by Location

The following table presents long-lived assets by location:

	June 30, 2020		December 31, 2019
	Unaudited		Audited
United States	$	10,249	$	8,896
Switzerland	1,719		3,067
Israel	3,736		2,753
Germany	982		729
Others	2,183		1,581
Total long-term assets	$	18,869	$	17,026

Schedule of Revenues by Geographic Region

The Company’s revenues by geographic region, based on the customer’s location, are summarized as follows:

	Three months ended June 30,				Six months ended June 30,				Year ended December 31, 2019
	2020		2019		2020		2019
	Unaudited				Unaudited				Audited
United States	$	81,209	$	58,934	$	150,468	$	105,538	$	232,805
EMEA:
Germany	21,469		21,097		43,271		42,377		86,564
Other EMEA	3,927		1,408		6,601		2,648		8,782
Japan	7,179		4,185		13,630		7,555		17,912
Greater China (1)	2,141		1,089		3,783		1,904		5,255
Total net revenues	$	115,925	$	86,713	$	217,753	$	160,022	$	351,318

(1) Reflects revenue recognized in accordance with a License and Collaboration Agreement (the “Zai Agreement”) between the Company and Zai Lab (Shanghai) Co., Ltd. (“Zai”), dated September 10, 2018, pursuant to which Zai is commercializing Optune in China, Hong Kong, Macau and Taiwan (referred to in this table as “Greater China”). In the three months ended June 30, 2020, the Company triggered a $8,000 milestone related to the approval of Optune for the treatment of GBM in China and in the six months ended June 30, 2020, the Company also triggered a $2,000 clinical trial milestone, each of which are being recognized over the remainder of the Zai performance period ending in September 2024. For additional information, see Note 12 to the Consolidated Financial Statements in the 2019 10-K.